Rgenta Therapeutics Scores $20M Seed Round Back to HomeCAMBRIDGE, MA, Rgenta Therapeutics announced it has closed a $20 Million seed investment, co-led by Boehringer Ingelheim Venture Fund and Matrix Partners China.

Rgenta Therapeutics, a new biotechnology company focusing on developing RNA-targeting medicines for historically undruggable disease-relevant targets, announced today that it closed a $20 Million seed investment, co-led by Boehringer Ingelheim Venture Fund and Matrix Partners China.

"We are delighted to have an outstanding syndicate of investors in this seed round," said Dr. Simon Xi, co-founder and CEO of Rgenta.

About Rgenta TherapeuticsRgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders.

Our lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases. | To read full story, visit https://startuparound.com/read/1586021406.0629396/Rgenta-Therapeutics-Scores-$20M-Seed-Round?ref=audio_experience